Oral Anticoagulation in Patients with Chronic Kidney Disease and Non-Valvular Atrial Fibrillation: The FAERC Study.
Marco MontomoliLourdes RocaMariana RiveraRaul Fernandez-PradoBeatriz RedondoRosa CamachoCayetana MoyanoSaul PampaAngela GonzalezJuan CasasMaria KislikovaAna Sanchez HorrilloAlicia Cabrera CárdenaBorja QuirogaCristina RabascoSara PiquerasAndrea SusoJavier Reque SantivañezJuan VillaRaquel OjedaDavid ArroyoPublished in: Healthcare (Basel, Switzerland) (2022)
Atrial fibrillation is highly prevalent in renal patients. Direct-acting anticoagulants seem to be associated with fewer ischemic-embolic complications, with no differences in bleeding, coronary events, or mortality rates.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- direct oral anticoagulants
- heart failure
- end stage renal disease
- ejection fraction
- percutaneous coronary intervention
- newly diagnosed
- coronary artery
- risk factors
- coronary artery disease
- cardiovascular events
- venous thromboembolism
- patient reported outcomes
- oxidative stress
- acute coronary syndrome
- left ventricular
- blood brain barrier
- transcatheter aortic valve replacement